Rani Therapeutics Holdings Inc’s filing revealed that its Director IMRAN MIR A acquired Company’s shares for reported $1.26 million on Oct 23 ’25. In the deal valued at $0.60 per share,2,083,334 shares were bought. As a result of this transaction, IMRAN MIR A now holds 2,083,334 shares worth roughly $3.1 million.
Then, South Cone Investments Limited sold 4,000,000 shares, generating $11,074,000 in total proceeds. Upon selling the shares at $2.77, the 10% Owner now owns 2,379,194 shares.
Before that, South Cone Investments Limited sold 1,923,000 shares. Rani Therapeutics Holdings Inc shares valued at $4,637,314 were divested by the 10% Owner at a price of $2.41 per share. As a result of the transaction, South Cone Investments Limited now holds 6,379,194 shares, worth roughly $9.5 million.
Oppenheimer initiated its Rani Therapeutics Holdings Inc [RANI] rating to an Outperform in a research note published on August 02, 2024; the price target was $17. A number of analysts have revised their coverage, including Maxim Group’s analysts, who began to cover the stock in mid June with a ‘”a Buy”‘ rating. Rodman & Renshaw began covering RANI with “Buy” recommendation on June 13, 2024.
Price Performance Review of RANI
On Monday, Rani Therapeutics Holdings Inc [NASDAQ:RANI] saw its stock jump 6.43% to $1.49. Over the last five days, the stock has gained 9.56%. Rani Therapeutics Holdings Inc shares have risen nearly 9.56% since the year began. Nevertheless, the stocks have risen 10.37% over the past one year.
How much short interest is there in Rani Therapeutics Holdings Inc?
A steep rise in short interest was recorded in Rani Therapeutics Holdings Inc stocks on 2025-12-31, growing by 3.28 million shares to a total of 13.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 10.6 million shares. There was a rise of 23.65%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 11, 2022 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
